BTK Mechanism in B Cells and Beyond; Therapeutic Implications for the Treatment of Immune-Mediated Diseases
Time: 11:30 am
day: Day Two
Details:
- Expression and role of BTK beyond B-cells
- Key mechanisms of action of BTK for targeting underlying drivers of immunemediated diseases
- Relating breadth of BTK pharmacology as it relates to the treatment of immunemediated diseases
Speakers:
Claire Langrish is the Vice President, Immunology and Biology, at Principia Biopharma. She is focused on the translation of drug and disease mechanisms, to discover and develop innovative therapies for immune-mediated diseases. During her post-doc at DNAX, Claire identified the key role of IL-23 in autoimmunity, and discovered Th17 cells, resulting in a dramatic shift in the…Read more